Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial.

Autor: Lacy BE; Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA., King J; Urovant Sciences, Irvine, California, USA., Shortino D; Urovant Sciences, Irvine, California, USA., Schaumburg C; Urovant Sciences, Irvine, California, USA., Haag-Molkenteller C; Urovant Sciences, Irvine, California, USA., Chey WD; Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan, USA.

Publikováno v: Neurogastroenterology and motility [Neurogastroenterol Motil] 2022 Dec; Vol. 34 (12), pp. e14448. Date of Electronic Publication: 2022 Aug 16.

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR.

Autor: Frankel J; Seattle Urology Research Center, Seattle, WA, USA., Staskin D; Tufts University School of Medicine, Boston, MA, USA., Varano S; Clinical Research Consulting, Milford, CT, USA., Kennelly M; Carolinas Medical Center, Charlotte, NC, USA., Newman DK; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Rosenberg MT; Mid-Michigan Health Centers, Jackson, MI, USA., Jankowich RA; Urovant Sciences, Irvine, CA, USA., Shortino D; Urovant Sciences, Irvine, CA, USA., Mudd PN Jr; Urovant Sciences, Irvine, CA, USA., Girman CJ; CERobs Consulting, LLC, 2612 Lumina Avenue North, Wrightsville Beach, Chapel Hill, NC, 28480, USA. cindy.girman@cerobs.com.

Publikováno v: Advances in therapy [Adv Ther] 2022 Feb; Vol. 39 (2), pp. 959-970. Date of Electronic Publication: 2021 Dec 18.

Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).

Autor: Staskin D; Tufts University School of Medicine, Boston, Massachusetts., Frankel J; Seattle Urology Research Center, Seattle, Washington., Varano S; Clinical Research Consulting, Milford, Connecticut., Shortino D; Urovant Sciences, Irvine, California., Jankowich R; Urovant Sciences, Irvine, California., Mudd PN Jr; Urovant Sciences, Irvine, California.

Publikováno v: The Journal of urology [J Urol] 2021 May; Vol. 205 (5), pp. 1421-1429. Date of Electronic Publication: 2020 Dec 28.

Vibegron improves quality-of-life measures in patients with overactive bladder: Patient-reported outcomes from the EMPOWUR study.

Autor: Frankel J; Seattle Urology Research Center, Seattle, WA, USA., Varano S; Clinical Research Consulting, Milford, CT, USA., Staskin D; Tufts University School of Medicine, Boston, MA, USA., Shortino D; Urovant Sciences, Irvine, CA, USA., Jankowich R; Urovant Sciences, Irvine, CA, USA., Mudd PN Jr; Urovant Sciences, Irvine, CA, USA.

Publikováno v: International journal of clinical practice [Int J Clin Pract] 2021 May; Vol. 75 (5), pp. e13937. Date of Electronic Publication: 2021 Jan 22.

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study.

Autor: Varano S; Geriatric Medicine, Clinical Research Consulting, 2080 Bridgeport Avenue, Suite D, Milford, CT, 06460, USA. varanos2@yahoo.com., Staskin D; Department of Surgery, Division of Urology, Tufts University School of Medicine, Boston, MA, USA., Frankel J; Urology, Seattle Urology Research Center, Seattle, WA, USA., Shortino D; Biostatistics, Urovant Sciences, Irvine, CA, USA., Jankowich R; Clinical Development, Urovant Sciences, Irvine, CA, USA., Mudd PN Jr; Clinical Development, Urovant Sciences, Irvine, CA, USA.

Publikováno v: Drugs & aging [Drugs Aging] 2021 Feb; Vol. 38 (2), pp. 137-146. Date of Electronic Publication: 2021 Jan 20.